Efficacy and Safety of Temodal vs Semustine in Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma (Study P03644)
The primary purpose of the study is to evaluate the efficacy and safety of temozolomide compared to semustine in the treatment of patients with glioblastoma multiforme or anaplastic astrocytoma.
Glioblastoma|Astrocytoma
DRUG: Temozolomide|DRUG: Semustine
Progression-free survival, 2 months, 3 months, and 6 months
Overall survival, 6 months|Objective response, 6 months|Scoring of health-related quality of life, 6 months
The primary purpose of the study is to evaluate the efficacy and safety of temozolomide compared to semustine in the treatment of patients with glioblastoma multiforme or anaplastic astrocytoma.